In November 2018, Ministry of Public Health and the Fight against AIDS (MPHFA) released an addendum on national guidelines for ARVs initiating the transition from ARV treatment to the new Dolutegravir-based therapy: Tenofovir / Lamivudine / Dolutegravir, known as TLD.
This treatment is for adults and teenagers over 35 pounds male and women over 49 years old.Service Yezu Mwiza followed suit with the MPHFA in implementing this approach through its Martin Royakers, S.J Clinic and by field trips with the Mobile Clinic.
Today we are reporting the case of MUTUMBA where the mobile clinic went for a monthly meeting in June.Out of 40 PLHIV on ARV treatment, 12 eligible patients were put on TLD. This has attracted the attention of PLHIV who are eager to discover this new treatment.
Note that according to WHO, TLD is recommended as a first-line alternative for HIV. Compared to other ARV molecules, this new treatment acts quickly in suppressing the viral load.
SYM: Distribution of school kits to members of associations of people affected by leprosy
SYM: Sensitization on pre and post-exposure to HIV in Kayanza and Ngozi
SYM: Managing co-morbidities among people living with HIV
SYM: Quarterly meeting of community relays
Distribution of work tools to young volunteers and to the pillars of the SRH community solutions project called
.png){kind=logo}
.png)
.png)
English 
French